AK106-001616, a Potent and Selective Inhibitor of Cytosolic Phospholipase A2: In Vivo Efficacy for Inflammation, Neuropathic Pain, and Pulmonary Fibrosis
Journal of Pharmacology and Experimental Therapeutics - United States
doi 10.1124/jpet.118.255034
Full Text
Open PDFAbstract
Available in full text
Date
April 10, 2019
Authors
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)